Literature DB >> 18190325

Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland.

Mohamed G Atta1, Derek M Fine, Gregory D Kirk, Shruti H Mehta, Richard D Moore, Gregory M Lucas.   

Abstract

BACKGROUND: African Americans with human immunodeficiency virus type 1 (HIV-1) infection and kidney disease are at increased risk of end-stage renal disease requiring renal replacement therapy (RRT), particularly in urban areas with high rates of poverty and injection drug use. It is unknown how the widespread use of highly active antiretroviral therapy (HAART) has affected survival during RRT in this vulnerable population.
METHODS: African American patients infected with HIV-1 who required RRT were identified from 2 cohorts that included 4509 Africans Americans infected with HIV-1 who were recruited during the period 1988-2004 in Baltimore, Maryland. Survival after initiation of RRT was compared for those who initiated treatment in the pre-HAART and the HAART eras using Kaplan-Meier curves. Cox proportional hazards regression analysis was used to adjust for potential confounders.
RESULTS: RRT was initiated in 162 patients (3.6%) during 10.6 years of follow-up (119 during the HAART era). Compared with patients who started RRT in the pre-HAART era, those in the HAART era were older (P<.001) and more likely to have CD4 cell counts of <or=200 cells/mm(3) (P=.01). A total of 126 patients (78%) died during follow-up; among those who initiated RRT during the HAART era, 87 deaths occurred (73%). Median survival time in the pre-HAART era was 22.4 months (95% confidence interval [CI], 9.3-30.7); during the HAART era, it was 19.9 months (95% CI, 14.7-26.5; P=.94). In the multiple Cox regression model, factors independently associated with increased mortality included age (hazard ratio [HR], 1.30; 95% CI, 1.06-1.60; P=.01), lower serum albumin level (HR, 0.72; 95% CI, 0.57-0.91; P<.007), lower CD4 cell count (HR, 0.90; 95% CI, 0.82-0.99; P<.03), and the lack of HAART (HR, 0.52; 95% CI, 0.33-0.82; P=.005).
CONCLUSIONS: Older age, lower serum albumin level, lower CD4 cell count, and the lack of HAART are independent predictors of poor survival among African Americans infected with HIV-1 undergoing RRT in a resource-limited urban area. RRT survival was similar in the pre-HAART and HAART eras, likely reflecting inadequate HIV treatment in this population.

Entities:  

Mesh:

Year:  2007        PMID: 18190325      PMCID: PMC4096866          DOI: 10.1086/523728

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants.

Authors:  D Vlahov; J C Anthony; A Munoz; J Margolick; K E Nelson; D D Celentano; L Solomon; B F Polk
Journal:  NIDA Res Monogr       Date:  1991

2.  Racial differences in the incidence of treatment for end-stage renal disease.

Authors:  S G Rostand; K A Kirk; E A Rutsky; B A Pate
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

3.  Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era.

Authors:  K C Abbott; I Hypolite; P G Welch; L Y Agodoa
Journal:  J Nephrol       Date:  2001 Sep-Oct       Impact factor: 3.902

4.  Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients.

Authors:  T S Ahuja; M Borucki; J Grady
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

Review 5.  HIV-associated nephropathy: an urban epidemic.

Authors:  M Monahan; N Tanji; P E Klotman
Journal:  Semin Nephrol       Date:  2001-07       Impact factor: 5.299

6.  Malnutrition as the main factor in morbidity and mortality of hemodialysis patients.

Authors:  S R Acchiardo; L W Moore; P A Latour
Journal:  Kidney Int Suppl       Date:  1983-12       Impact factor: 10.545

7.  Is there an epidemic of HIV Infection in the US ESRD program?

Authors:  Paul W Eggers; Paul L Kimmel
Journal:  J Am Soc Nephrol       Date:  2004-09       Impact factor: 10.121

8.  Outcome of patients with human immunodeficiency virus on maintenance hemodialysis.

Authors:  C Ortiz; R Meneses; D Jaffe; J A Fernandez; G Perez; J J Bourgoignie
Journal:  Kidney Int       Date:  1988-08       Impact factor: 10.612

9.  Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.

Authors:  E G Lowrie; N L Lew
Journal:  Am J Kidney Dis       Date:  1990-05       Impact factor: 8.860

10.  Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States.

Authors:  Tejinder S Ahuja; James Grady; Shilpi Khan
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

View more
  15 in total

1.  Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition.

Authors:  Guangtao Zhang; Ruijie Liu; Yifei Zhong; Alexander N Plotnikov; Weijia Zhang; Lei Zeng; Elena Rusinova; Guillermo Gerona-Nevarro; Natasha Moshkina; Jennifer Joshua; Peter Y Chuang; Michael Ohlmeyer; John Cijiang He; Ming-Ming Zhou
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

2.  End-stage renal disease among HIV-infected adults in North America.

Authors:  Alison G Abraham; Keri N Althoff; Yuezhou Jing; Michelle M Estrella; Mari M Kitahata; C William Wester; Ronald J Bosch; Heidi Crane; Joseph Eron; M John Gill; Michael A Horberg; Amy C Justice; Marina Klein; Angel M Mayor; Richard D Moore; Frank J Palella; Chirag R Parikh; Michael J Silverberg; Elizabeth T Golub; Lisa P Jacobson; Sonia Napravnik; Gregory M Lucas
Journal:  Clin Infect Dis       Date:  2014-11-18       Impact factor: 9.079

Review 3.  Pharmacotherapy and treatment options for HIV-associated nephropathy.

Authors:  Steven Menez; Mohamad Hanouneh; Blaithin A McMahon; Derek M Fine; Mohamed G Atta
Journal:  Expert Opin Pharmacother       Date:  2017-12-26       Impact factor: 3.889

4.  Detection of human immunodeficiency virus-1 ribonucleic acid in the peritoneal effluent of renal failure patients on highly active antiretroviral therapy.

Authors:  Kwazi C Z Ndlovu; Wilbert Sibanda; Alain Assounga
Journal:  Nephrol Dial Transplant       Date:  2017-04-01       Impact factor: 5.992

5.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian
Journal:  Clin Infect Dis       Date:  2014-09-17       Impact factor: 9.079

6.  HIV and proteinuria in an injection drug user population.

Authors:  Elizabeth L Yanik; Gregory M Lucas; David Vlahov; Gregory D Kirk; Shruti H Mehta
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-12       Impact factor: 8.237

Review 7.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Renal transplantation in patients with HIV.

Authors:  Lynda A Frassetto; Clara Tan-Tam; Peter G Stock
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

9.  Organ Transplantation in HIV Patients: Current Status and New Directions.

Authors:  Valentina Stosor
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

10.  Solid Organ Transplantation for HIV-Infected Individuals.

Authors:  Ashton A Shaffer; Christine M Durand
Journal:  Curr Treat Options Infect Dis       Date:  2018-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.